Technical Analysis for BIVV - Bioverativ Inc

Grade Last Price % Change Price Change
grade B 64.11 2.17% 1.36
BIVV closed up 2.17 percent on Friday, January 19, 2018, on 61 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BIVV trend table...

Date Alert Name Type % Chg
Jan 19 New 52 Week Closing High Bullish 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 18 NR7 Range Contraction 2.17%
Jan 18 Upper Bollinger Band Walk Strength 2.17%
Jan 18 Wide Bands Range Expansion 2.17%
Jan 18 Overbought Stochastic Strength 2.17%
Jan 17 Slingshot Bullish Bullish Swing Setup 2.87%
Jan 17 Upper Bollinger Band Walk Strength 2.87%
Jan 17 Wide Bands Range Expansion 2.87%

Older signals for BIVV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Is BIVV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 65.09
52 Week Low 41.88
Average Volume 1,156,473
200-Day Moving Average 56.9539
50-Day Moving Average 54.3964
20-Day Moving Average 57.6405
10-Day Moving Average 60.822
Average True Range 1.7811
ADX 37.55
+DI 39.09
-DI 12.51
Chandelier Exit (Long, 3 ATRs ) 59.7467
Chandelier Exit (Short, 3 ATRs ) 58.2533
Upper Bollinger Band 65.5289
Lower Bollinger Band 49.7521
Percent B (%b) 0.91
BandWidth 27.371033
MACD Line 2.7231
MACD Signal Line 1.9877
MACD Histogram 0.7354
Fundamentals Value
Market Cap 6.93 Billion
Num Shares 108 Million
EPS 4.21
Price-to-Earnings (P/E) Ratio 15.23
Price-to-Sales 5.99
Price-to-Book 9.21
PEG Ratio 1.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.38
Resistance 3 (R3) 66.14 65.16 66.00
Resistance 2 (R2) 65.16 64.58 65.27 65.87
Resistance 1 (R1) 64.63 64.22 64.90 64.87 65.75
Pivot Point 63.65 63.65 63.78 63.76 63.65
Support 1 (S1) 63.12 63.07 63.39 63.36 62.47
Support 2 (S2) 62.14 62.71 62.25 62.35
Support 3 (S3) 61.61 62.14 62.22
Support 4 (S4) 61.85